Juniper Networks Inc
Total Consideration
$13.63B
Share price: $40.00
Purchase-Price Allocation
Goodwill
$7.27B
Assets Acquired
$19.07B
Liabilities Assumed
$5.45B
Pro-Forma Combined Entity
Revenue
$38.09B
Net Income
+$108.0M
3 years of history · ending 2025-10-31 · SEC EDGAR
Three classic accounting-quality scores. F-Score (0-9, higher = better fundamentals); M-Score (>-1.78 flags possible manipulation); Z-Score (>2.99 = safe, <1.81 = distressed). Use together — single-score readings are noisy.
Per-quarter consensus estimates + actuals + beat/miss surprise. Sourced from Finnhub (Wall Street consensus aggregation).
Source caveat: Finnhub free tier returns the consensus mean only — analyst high / low / dispersion + analyst counts require a paid plan. A "$5.00 consensus" line above could mean "20 analysts at exactly $5" (high conviction) or "10 at $5.50, 10 at $4.50" (split). Treat single-line consensus accordingly.
Bridges from the federal statutory rate (21% post-TCJA) to the effective tax rate via the issuer's tax-note reconciliation lines. Sourced from EffectiveIncomeTaxRateReconciliation* flat CompanyFacts concepts. Conditional lines (R&D credits, FDII, SBC, valuation allowance, etc.) only render when the issuer discloses them. Persistent divergence between accrual tax expense and cash taxes paid is a leading signal for deferred-tax buildup.
Effective Rate Trend
| Reconciliation Line | FY2020 | FY2021 | FY2022 | FY2023 | FY2024 | FY2025 |
|---|---|---|---|---|---|---|
| Federal Statutory Rate | 21.00% | 21.00% | 21.00% | 21.00% | 21.00% | 21.00% |
| State & Local Income Taxes | 0.90% | 0.70% | 2.80% | 0.90% | 0.40% | 24.40% |
| Foreign Rate Differential | -2.30% | -7.60% | -0.90% | -4.40% | -1.30% | 66.50% |
| Other Adjustments | -0.20% | 0.10% | 2.70% | 0.10% | 0.00% | — |
| R&D Tax Credits | -8.40% | 1.30% | 5.10% | 2.10% | 1.80% | -22.70% |
| Nondeductible Expenses | -3.40% | 3.60% | 6.00% | -1.50% | -4.00% | -23.50% |
| Valuation Allowance Change | 20.80% | -10.00% | -31.50% | -2.80% | -1.30% | -14.70% |
| Tax Law Change | 15.50% | -1.10% | 0.00% | 0.00% | 0.00% | 114.60% |
| Effective Tax Rate | 27.10% | 4.50% | 0.90% | 9.20% | 12.70% | 120.00% |
Cash vs Accrual
| Item | FY2020 | FY2021 | FY2022 | FY2023 | FY2024 | FY2025 |
|---|---|---|---|---|---|---|
| Income Tax Expense (Accrual) | −$120.0M | $160.0M | $8.0M | $205.0M | $374.0M | −$342.0M |
| Income Taxes Paid (Cash) | $297.0M | $398.0M | $107.0M | $307.0M | $248.0M | $425.0M |
Per-deal acquisition disclosures sourced from us-gaap:BusinessAcquisitionAxis dimensional XBRL. Each card surfaces the deal's purchase-price allocation (goodwill vs intangibles vs liabilities), contingent consideration (unpaid earn-outs), and pro-forma combined-entity numbers. Probability-of-Success (PoS) factor on biotech targets is the ASC 805 contingent-consideration valuation — higher = closer to commercialization, higher implied target value.
Total Consideration
$13.63B
Share price: $40.00
Purchase-Price Allocation
Goodwill
$7.27B
Assets Acquired
$19.07B
Liabilities Assumed
$5.45B
Pro-Forma Combined Entity
Revenue
$38.09B
Net Income
+$108.0M
Purchase-Price Allocation
Goodwill
$585.0M
Assets Acquired
$46.0M
Total Consideration
$412.0M
Purchase-Price Allocation
Goodwill
$311.0M
Total Consideration
$307.0M
Purchase-Price Allocation
Goodwill
$217.0M
Total Consideration
$147.0M
Purchase-Price Allocation
Goodwill
$98.0M
Liabilities Assumed
$19.0M
Per-category restructuring disclosures sourced from us-gaap:RestructuringCostAndReserveAxis dimensional XBRL. Negative charges indicate reversals of prior accruals (a sign the original estimate was too aggressive — flattering current-period earnings).
As of 2025-10-31
| Category | Class | P&L Charge | Cash Paid | Reserve Balance |
|---|---|---|---|---|
| Infrastructure And Other Restructuring Items | Other | −$10M | $21M | $61M |
| Employee Severance | Employee Severance | — | $32M | $37M |
Phase 1: currency selection stored in the URL. Conversion ships in Phase 2 (see ADR-0003).